Condition
Malignant Pleural Mesothelioma|Nonsquamous Nonsmall Cell Neoplasm of Lung
Estimated Enrollment: 31
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: ONC-2011-001
Study First Received: May 24, 2013
Last Updated: February 9, 2017
Estimated Primary Completion Date: May 2016
Primary Outcome Measures:
To determine the dose limiting toxicities (DLTs) of Tivantinib|To determine the pharmacokinetics profile of Tivantinib in combination with Carboplatin and Pemetrexed|To assess the preliminary anti-tumor activity of Tivantinib with PFS|To assess the preliminary anti-tumor activity of Tivantinib with RECIST|To evaluate dynamic changes in blood levels|To evaluate the expression of biomarkers|To dermine the MTD of combination|To assess the preliminary anti-tumor activity of tivantinib
Sponsors and Collaborators:
Armando Santoro, MD|Istituto Clinico Humanitas
Website Link: https://ClinicalTrials.gov/show/NCT02049060
